Headquartered in Switzerland, Ferring has locations worldwide, including 13 manufacturing facilities and 12 R&D centers, and major operations in 11 countries, including the U.S. In the U.S., our portfolio spans reproductive medicine and maternal health, gastroenterology, and orthopedics. Our products are distributed in 110 countries around the world, reaching millions of patients in need. We currently have operating subsidiaries in nearly 60 countries.
Parsippany, New Jersey
Our location in Parsippany, NJ, is the hub of our U.S. operations, including an on-site manufacturing facility. We’ve invested nearly $160 million in the creation of our U.S. headquarters. This state-of-the-art facility brings together clinical development, product supply and commercialization groups all under one roof. The complex sits on a 25-acre site and employs approximately 400 people in manufacturing, commercial operations, clinical development, management and administration. It’s where our people share ideas to ultimately develop, manufacture and market new therapies to help people build families, stay healthy and fight disease.
Ferring Research Institute, Inc.
San Diego, California
Ferring Research Institute, Inc., (FRI) is the research and ideas incubator of Ferring Pharmaceuticals. Established in 1996, FRI is located in the heart of the Southern California biopharmaceutical community. The center has attracted a diverse group of highly skilled professionals representing over twenty-four countries of origin. FRI is our key research center for early research and development. Here, our scientists work on small molecule and peptide drug discovery, from new target identification up until early drug development phases. FRI is focused on the following key therapeutic areas: reproductive medicine and maternal health, uro-oncology, gastroenterology and the microbiome.
Our state-of-the art facility includes peptide and protein drug design, chemistry, pharmacology, biology, and preclinical pharmacokinetics capabilities. Historically FRI has focused on the discovery of amino acid-based therapeutics utilizing the body’s signaling hormones. Today FRI is committed to building a portfolio of novel, innovative therapeutics using a wide array of modalities in order to address areas of high unmet medical need in our core therapeutic areas. Driving value through personalized medicine.
Rebiotix – A Ferring Company
We’re not only investigating the microbiome to help people with certain diseases live better lives, we’re also using our learnings to understand its implications for bigger health challenges like cancer, chronic disease and other debilitating conditions.
Ferring’s late-stage clinical microbiome center, Rebiotix Inc. in Roseville, Minnesota, focuses on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. We have a diverse pipeline of investigational drug products built on the pioneering microbiota-based MRT™ drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract.
Our microbiome team includes a passionate team of scientists, engineers and clinical researchers motivated by the opportunity to pioneer new therapies and technologies to meet today’s medical needs.
Learn more about our history